Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stopping boundaries adjusted for sample size reestimation and negative stop.

Zhenming Shun1

  • 1Aventis Pharmaceuticals Inc., BX2-400C, 200 Crossing Blvd., Bridgewater, NJ 08807, USA. zhenming.shun@aventis.com

Journal of Biopharmaceutical Statistics
|December 13, 2002
PubMed
Summary

This study introduces a flexible group sequential method for clinical trials, allowing for sample size reestimation and early stopping while controlling Type I error rates. This approach enhances trial efficiency and integrity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer.

Therapeutic advances in medical oncology·2022
Same author

Reply to M. Horiguchi et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018
Same author

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

The Lancet. Haematology·2017
Same author

A note on sequential monitoring of select-the-winner design.

Journal of biopharmaceutical statistics·2015
Same author

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

Cancer·2013
Same author

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2010

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Statistical Methods

Background:

  • Group sequential methods and sample size reestimation are crucial for adaptive clinical trial design.
  • Controlling Type I error is paramount during interim analyses with adaptive designs.
  • Existing methods may not fully integrate sample size adjustments with sequential stopping rules.

Purpose of the Study:

  • To propose a novel approach for specifying group sequential stopping boundaries.
  • To adjust boundaries for sample size reestimation and negative stops in interim analyses.
  • To maintain overall Type I error control in adaptive clinical trials.

Main Methods:

  • Developing group sequential stopping boundaries adjusted for sample size reestimation.

Related Experiment Videos

  • Incorporating potential Type I error changes from sample size adjustments and negative stops.
  • Utilizing closed mathematical forms for precise boundary adjustments.

    • Main Results:

    • The proposed method effectively controls the overall Type I error rate.
    • Adjustments to stopping boundaries minimize penalties for Type I error inflation.
    • The approach offers greater efficiency compared to using group sequential or sample size reestimation methods alone.

    Conclusions:

    • This integrated approach provides flexibility in clinical trial design while preserving statistical integrity.
    • The method ensures robust control of Type I error even with adaptive modifications.
    • It represents an advancement in statistical methodologies for clinical trials, balancing efficiency and validity.